# Invesco STOXX Europe 600 Optimised Health Care UCITS ETF (0MT7)

**Page:** https://fundology.uk/fund/0mt7 · ISIN IE00B5MJYY16

## At a glance

> Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.

As of 20/11/2026, 0MT7 (Invesco STOXX Europe 600 Optimised Health Care UCITS ETF, ISIN IE00B5MJYY16) closed at €456.50 on the London Stock Exchange. Its ongoing charge is 0.20% a year (about £20 on £10,000). Over the five years to 20/11/2026 its total return was +25.7%, or −1.4% after UK CPIH inflation.

## Summary

Invesco STOXX Europe 600 Optimised Health Care UCITS ETF is an exchange-traded fund (ETF) from Invesco, launched in 2009. It tracks the STOXX Europe 600 Optimised Health Care Index — large and medium-sized European companies. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.2% a year — about £20 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.

Latest close: **€456.50** (20/11/2026).

## Key facts

| Fact | Value |
|---|---|
| Ticker (LSE) | 0MT7 |
| ISIN | IE00B5MJYY16 |
| Also listed as | SC0T (Xetra, euros) |
| Category | Healthcare |
| Type | ETF |
| Provider | Invesco |
| Tracks | STOXX Europe 600 Optimised Health Care Index |
| Income | Accumulating |
| Ongoing charge | 0.20% a year (£20 per £10,000) |
| Fund size | £10.9m |
| Launched | 2009 |
| Domicile | Ireland |
| UK reporting fund status | Yes — on HMRC’s list of reporting funds (list of 02/11/2026); reporting fund since 01/12/2009 |

## Past returns (periods to 20/11/2026)

After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after UK CPIH inflation.

| Window | Return | After CPIH inflation | Measured as |
|---|---|---|---|
| 1 year | +6.96% | +3.18% | income reinvested |
| 3 years | +25.52% | +13.02% | income reinvested |
| 5 years | +25.72% | -1.40% | income reinvested |

Returns: as reported (delayed data). Inflation: UK CPIH, latest month published.

## Charges compared with similar funds

Ongoing charge of Invesco STOXX Europe 600 Optimised Health Care UCITS ETF 0.20% a year. Compared on 21/11/2026, 19 of the 28 other healthcare funds charge more, 1 the same and 8 less (share classes counted once).

## Charges & eligibility

- Ongoing charges figure (OCF): **0.20%** per year (as of 20/11/2026)
- Stocks and shares ISA eligible: usually (check with your platform)
- SIPP eligible: usually (check with your provider)
- ISA and SIPP mean the kind of product usually qualifies under HMRC rules. We do not check each platform’s list — each provider decides which funds it offers. Crypto ETNs have not qualified for a stocks and shares ISA since 06/04/2026, and overseas funds that are not UK-recognised UCITS, such as Swiss ETFs, do not usually qualify.

## What it holds

As of 03/11/2026, 0MT7 holds 43 positions, according to its published holdings. The largest is AstraZeneca at 10.55% of the fund; the ten largest make up 66.1%.

### Top holdings

Largest positions (as of 03/11/2026), as a percentage of the whole fund:

| # | Holding | Ticker | Weight |
|---|---|---|---|
| 1 | AstraZeneca | [AZN](https://fundology.uk/stock/AZN) | 10.55% |
| 2 | Novartis | [NOVN](https://fundology.uk/stock/NOVN) | 10.54% |
| 3 | Roche | [RO](https://fundology.uk/stock/RO) | 10.17% |
| 4 | Novo Nordisk | [NOVO_B](https://fundology.uk/stock/NOVO_B) | 7.34% |
| 5 | Sanofi | [SAN](https://fundology.uk/stock/EURONEXT:SAN) | 6.60% |
| 6 | GSK | [GSK](https://fundology.uk/stock/GSK) | 6.46% |
| 7 | EssilorLuxottica | [EL](https://fundology.uk/stock/EL) | 4.22% |
| 8 | Bayer | [BAYN](https://fundology.uk/stock/BAYN) | 3.71% |
| 9 | Lonza Group | [LONN](https://fundology.uk/stock/LONN) | 3.63% |
| 10 | Sandoz Group | [SDZ](https://fundology.uk/stock/SDZ) | 2.89% |

## Where it invests

Shares of the whole fund. Bonds, cash and positions without a classification are shown as they come, not guessed.

### By sector

As published for the fund, as of 03/11/2026.

| Sector | Weight |
|---|---|
| Health Care | 98.4% |
| Materials | 1.6% |

### By country

As published for the fund, as of 03/11/2026.

| Country | Weight |
|---|---|
| Switzerland | 21.8% |
| United Kingdom | 21.0% |
| United States | 20.3% |
| Denmark | 12.1% |
| Germany | 9.1% |
| France | 5.9% |
| Belgium | 5.4% |
| Netherlands | 1.6% |
| Other countries | 2.8% |

All 43 holdings: https://fundology.uk/fund/0mt7/holdings

## Questions people ask

**What is the ongoing charge of 0MT7?**

The ongoing charge of 0MT7 is 0.20% a year — about £20 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of Invesco STOXX Europe 600 Optimised Health Care UCITS ETF 0.20% a year. Compared on 21/11/2026, 19 of the 28 other healthcare funds charge more, 1 the same and 8 less (share classes counted once).

**What does 0MT7 track?**

0MT7 tracks the STOXX Europe 600 Optimised Health Care Index — large and medium-sized European companies.

**Is 0MT7 accumulating or distributing?**

0MT7 is accumulating: income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.

**What is the ISIN of 0MT7?**

The ISIN of 0MT7 is IE00B5MJYY16. An ISIN identifies one exact share class of a fund; 0MT7 is its ticker on the London Stock Exchange. The same share class is also listed as SC0T (Xetra, euros).

**What does 0MT7 hold?**

As of 03/11/2026, 0MT7 holds 43 positions, according to its published holdings. The largest is AstraZeneca at 10.55% of the fund; the ten largest make up 66.1%. Its ten largest holdings are AstraZeneca (10.55%), Novartis (10.54%), Roche (10.17%), Novo Nordisk (7.34%), Sanofi (6.60%), GSK (6.46%), EssilorLuxottica (4.22%), Bayer (3.71%), Lonza Group (3.63%) and Sandoz Group (2.89%).

**How has 0MT7 done after inflation?**

Over the five years to 20/11/2026 0MT7’s total return was +25.7%, or −1.4% after UK CPIH inflation. Past performance is not a guide to future returns.

---

We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments.

Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.
